Radiopharmaceutical Therapy

1. Auflage 2023
ISBN: 978-3-031-39004-3
Verlag: Springer

Buch, Englisch, 564 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 1394 g

This book covers foundational topics in the emerging field of radiopharmaceutical therapy. It is divided into three sections: fundamentals, deeper dives, and special topics. In the first section, the authors examine the field from a bird’s-eye view, covering topics including the history of radiopharmaceutical therapy, the radiobiology of radiopharmaceutical therapy, and the radiopharmaceutical chemistry of both metallic and non-metallic radionuclides. The second section provides a more in-depth look at specific radiotherapeutics. Chapters include broader discussions of the different platforms for radiopharmaceutical therapy as well as more focused case studies covering individual radiotherapeutics. The third and final section explores a number of areas for further study, including medical physics, artificial intelligence, in vivo pretargeting, theranostic imaging, and the regulatory review process for radiotherapeutics.

This book is the first of its kind and is useful for a broad audience of scientists, researchers, physicians, and students across a range of fields, including biochemistry, cancer biology, nuclear medicine, radiology, and radiation oncology.

Zielgruppe

Research

Autoren/Hrsg.

Bodei, Lisa

Lewis, Jason S.

Zeglis, Brian M.

Fachgebiete

• Naturwissenschaften Chemie Physikalische Chemie Nuklearchemie, Photochemie, Strahlenchemie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Naturwissenschaften Physik Angewandte Physik Medizinische Physik
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

Preface

Foreword

Section 1. Fundamentals             

Chapter 1. Introduction: The Case for Endoradiotherapy

Chapter 2. The History of Endoradiotherapy

Chapter 3. The Nuclear Chemistry of Therapeutic Radionuclides

Chapter 4. The Production of Therapeutic Radionuclides

Chapter 5. The Radiobiology of Alpha Particles, Beta Particles, and Auger Electrons

Chapter 6. The Radiopharmaceutical Chemistry of Metallic Radionuclides

Chapter 7. The Radiopharmaceutical Chemistry of Non-Metallic Radionuclides

Chapter 8. Dosimetry in Endoradiotherapy

Section 2. Deeper Dives

9. Antibodies as Vectors for Endoradiotherapy

Chapter 10. Case Study #1: 225Ac-Labeled IgG

Chapter 11. Case Study #2: 131I-3F8

Chapter 12. Case Study #3: Antibody Fragments in Endoradiotherapy

Chapter 13. Peptides as Vectors for Endoradiotherapy

Chapter 14. Case Study #4: LUTATHERA

Chapter 15. Case Study #5: CXCR4

Chapter 16. Case Study #6: JR11

Chapter 17. Small Molecules as Vectors for Endoradiotherapy

Chapter 18. Case Study #7: PSMA-617

Chapter 19. Case Study #8: 223RaCl3

Section 3. Special Topics               

Chapter 20. Auger Emitters in Endoradiotherapy

Chapter 21. In Vivo Pretargeting

Chapter 22. Theranostic Imaging and Endoradiotherapy

Chapter 23. The Next Generation of Therapeutic Radionuclides

Chapter 24. Artificial Intelligence and Machine Learning

Chapter 25. The Regulatory Review of Radiotherapeutics: USA

Chapter 26. The Regulatory Review of Radiotherapeutics: Europe

Chapter 27. The Regulatory Review of Radiotherapeutics: Japan

Chapter 28. Radiotherapeutics in the Nuclear Pharmacy

Chapter 29. The Future

Über Autor(innen)

Lisa Bodei, MD, PhD is a nuclear medicine physician with extensive experience and expertise in therapeutic and diagnostic applications of nuclear medicine in oncology, particularly with theranostics and the application of genomic technology to further defining the efficacy of theranostics. She is the Director of the Targeted Radionuclide Therapy Section of the Molecular Imaging and Therapy Service in the Department of Radiology, MSKCC. She has authored more than 200 peer-reviewed publications and serves on the editorial boards of several scientific journals.

Jason S. Lewis, PhD, is the Emily Tow Chair, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility in the Department of Radiology, MSKCC. He heads a laboratory in the Sloan Kettering Institute’s molecular pharmacology program and is a professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. He has published more than 300 papers, books, book chapters, and reviews on cancer imaging and therapy.

Brian M. Zeglis, PhD, received his scientific training at Yale University, the California Institute of Technology, and Memorial Sloan Kettering Cancer Center before starting his own lab at Hunter College of the City University of New York in 2015. His current research is focused on the synthesis, in vivo validation, and clinical translation of radiopharmaceuticals for the imaging and therapy of disease, with a particular emphasis on investigations at the intersection of radiochemistry and bioorthogonal chemistry.